Syndax Pharmaceuticals (SNDX) Current Assets (2015 - 2026)

Syndax Pharmaceuticals' Current Assets history runs 12 years deep, the most recent figure standing at $471.2 million for Q1 2026.

• On a quarterly basis, Current Assets fell 14.14% year-over-year to $471.2 million in Q1 2026; TTM through Mar 2026 was $471.2 million, a 14.14% decrease from a year earlier, with the FY2025 full-year figure at $528.1 million, down 12.43% from the prior year.
• Current Assets eased to $471.2 million in Q1 2026 per SNDX's latest filing, from $528.1 million in the prior quarter.
• Across five years, Current Assets topped out at $603.1 million in Q4 2024 and bottomed at $357.6 million in Q3 2022.
• The 5-year median for Current Assets is $453.9 million (2024), against an average of $470.6 million.
• Across the five-year window, Current Assets soared 50.59% in 2022 and fell 14.14% in 2026, its largest moves.
• Year by year, Current Assets stood at $489.8 million in 2022, then climbed by 18.6% to $580.9 million in 2023, then advanced by 3.82% to $603.1 million in 2024, then retreated by 12.43% to $528.1 million in 2025, then retreated by 10.78% to $471.2 million in 2026.
• Per Business Quant, the three latest SNDX Current Assets figures stand at $471.2 million (Q1 2026), $528.1 million (Q4 2025), and $529.8 million (Q3 2025).